Characteristics of the study population at AML diagnosis
| Characteristic . | Overall . | Monoblastshigh . | Monoblastslow . | P value . |
|---|---|---|---|---|
| N = 86 . | n = 34 . | n = 52 . | ||
| Sex at birth | .8 | |||
| Female | 39 (45) | 16 (47) | 23 (44) | |
| Male | 47 (55) | 18 (53) | 29 (56) | |
| Age | 73 [69-77] (20-85) | 73 [69-78] (20-85) | 73 [68-76] (25-85) | .8 |
| WBC, ×109/L | 5 [2-18] (0-229) | 11 [4-23] (1-229) | 4 [2-10] (0-69) | .014 |
| FAB category | <.001 | |||
| M4/5 | 26 (30) | 22 (65) | 4 (8) | |
| Non-M4/5 | 60 (70) | 12 (35) | 48 (92) | |
| Performance status | .3 | |||
| 0-2 | 74 (86) | 31 (91) | 43 (83) | |
| >2 | 12 (14) | 3 (9) | 9 (17) | |
| Clinical ontogeny | ||||
| De novo | 63 (73) | 24 (70) | 39 (75) | .7 |
| Secondary AML | 23 (27) | 10 (30) | 13 (25) | .7 |
| Therapy related | 18 (21) | 7 (21) | 11 (21) | >.9 |
| ELN 2022 classification | .3 | |||
| Favorable | 5 (6) | 1 (3) | 4 (8) | |
| Intermediate | 6 (7) | 4 (12) | 2 (4) | |
| Adverse | 75 (87) | 29 (85) | 46 (88) | |
| ELN 2024 classification | .084 | |||
| Favorable | 36 (42) | 12 (35) | 24 (46) | |
| Intermediate | 24 (28) | 14 (41) | 10 (19) | |
| Adverse | 26 (30) | 8 (24) | 18 (35) | |
| Follow-up, mo | 23.7 [14.9-35.8] (0.5-54.2) | 26.6 [8.1-27.6] (0.5-31.0) | 21.5 [14.9-30] (0.5-54.2) | .01 |
| No. of Ven-Aza cycles | 3 [2-7] (1-25) | 2 [2-4] (1-18) | 5 [2-9] (1-25) | .032 |
| Allogeneic hematopoietic cell transplantation | 6/86 (7) | 0/34 (0) | 6/52 (12) | .077 |
| Characteristic . | Overall . | Monoblastshigh . | Monoblastslow . | P value . |
|---|---|---|---|---|
| N = 86 . | n = 34 . | n = 52 . | ||
| Sex at birth | .8 | |||
| Female | 39 (45) | 16 (47) | 23 (44) | |
| Male | 47 (55) | 18 (53) | 29 (56) | |
| Age | 73 [69-77] (20-85) | 73 [69-78] (20-85) | 73 [68-76] (25-85) | .8 |
| WBC, ×109/L | 5 [2-18] (0-229) | 11 [4-23] (1-229) | 4 [2-10] (0-69) | .014 |
| FAB category | <.001 | |||
| M4/5 | 26 (30) | 22 (65) | 4 (8) | |
| Non-M4/5 | 60 (70) | 12 (35) | 48 (92) | |
| Performance status | .3 | |||
| 0-2 | 74 (86) | 31 (91) | 43 (83) | |
| >2 | 12 (14) | 3 (9) | 9 (17) | |
| Clinical ontogeny | ||||
| De novo | 63 (73) | 24 (70) | 39 (75) | .7 |
| Secondary AML | 23 (27) | 10 (30) | 13 (25) | .7 |
| Therapy related | 18 (21) | 7 (21) | 11 (21) | >.9 |
| ELN 2022 classification | .3 | |||
| Favorable | 5 (6) | 1 (3) | 4 (8) | |
| Intermediate | 6 (7) | 4 (12) | 2 (4) | |
| Adverse | 75 (87) | 29 (85) | 46 (88) | |
| ELN 2024 classification | .084 | |||
| Favorable | 36 (42) | 12 (35) | 24 (46) | |
| Intermediate | 24 (28) | 14 (41) | 10 (19) | |
| Adverse | 26 (30) | 8 (24) | 18 (35) | |
| Follow-up, mo | 23.7 [14.9-35.8] (0.5-54.2) | 26.6 [8.1-27.6] (0.5-31.0) | 21.5 [14.9-30] (0.5-54.2) | .01 |
| No. of Ven-Aza cycles | 3 [2-7] (1-25) | 2 [2-4] (1-18) | 5 [2-9] (1-25) | .032 |
| Allogeneic hematopoietic cell transplantation | 6/86 (7) | 0/34 (0) | 6/52 (12) | .077 |
Frequency (%) and median with (IQR) and ranges [minimum to maximum] are shown for categorial and continuous variables, respectively.